Skip to main content
Log in

Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Heart failure (HF) is a condition associated with the apoptosis and cell death of both cardiac myocytes and cardiac non-myocytes. DNA fragments released from programmed cell death or acute cellular injury are the main sources of disease-associated elevation of cell-free (cf) DNA. We hypothesized that cfDNA could be a relevant marker of cardiac apoptosis in HF patients that could be affected by the improvement of myocardial performance. To test our hypothesis, we measured plasma cfDNA in 19 patients with ischemic HF and severe left ventricular (LV) systolic dysfunction before and 12 h after completion of levosimendan infusion. Echocardiographic and biochemical markers of LV diastolic pressure and LV systolic function were also assessed. In accordance with previous observations levosimendan improved echocardiographic and biochemical indices of LV function. Plasma cfDNA was significantly reduced in HF patients post-levosimendan treatment (median: 89.4, interquartile range: 87.1 to median: 25.9, interquartile range: 12.3, P = 0.028). Notably, in 15/19 patients there was a reduction in cfDNA levels post-levosimendan infusion; while in 12/19 patients, a more than 50% reduction in plasma cfDNA was observed. Since cfDNA is a marker of tissue injury and apoptosis these results indicate that improvement of LV function has a potential impact on cell preservation and survival. Further studies are needed to substantiate our promising results regarding the role of plasma cfDNA as a marker of HF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Sozzi G, Conte D, Leon M et al (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21:3902–3908

    Article  CAS  PubMed  Google Scholar 

  2. Chun FK, Muller I, Lange I et al (2006) Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int 98:544–548

    Article  CAS  PubMed  Google Scholar 

  3. Goebel G, Zitt M, Muller HM (2005) Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 21:105–120

    CAS  PubMed  Google Scholar 

  4. Boddy JL, Gal S, Malone PR, Harris AL, Wainscoat JS (2005) Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res 11:1394–1399

    Article  CAS  PubMed  Google Scholar 

  5. Jung K, Fleischhacker M, Rabien A (2010) Cell-free DNA in the blood as a solid tumor biomarker—a critical appraisal of the literature. Clin Chim Acta 411(21–22):1611–1624

    Article  CAS  PubMed  Google Scholar 

  6. Gupta AK, Holzgreve W, Huppertz B, Malek A, Schneider H, Hahn S (2004) Detection of fetal DNA and RNA in placenta-derived syncytiotrophoblast microparticles generated in vitro. Clin Chem 50:2187–2190

    Article  CAS  PubMed  Google Scholar 

  7. Bauer M, Hutterer G, Eder M et al (2006) A prospective analysis of cell-free fetal DNA concentration in maternal plasma as an indicator for adverse pregnancy outcome. Prenat Diagn 26:831–836

    Article  CAS  PubMed  Google Scholar 

  8. Zhong XY, Holzgreve W, Hahn S (2002) The levels of circulatory cell-free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy 21:77–183

    Article  CAS  PubMed  Google Scholar 

  9. Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, Wu JT (2003) Elevated cell-free serum DNA detected in patients with myocardial infarction. Clin Chim Acta 327:95–101

    Article  CAS  PubMed  Google Scholar 

  10. Raptis L, Menard HA (1980) Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J Clin Invest 66:1391–1399

    Article  CAS  PubMed  Google Scholar 

  11. Uzuelli JA, Dias-Junior CA, Izidoro-Toledo TC, Gerlach RF, Tanus-Santos JE (2009) Circulating cell-free DNA levels in plasma increase with severity in experimental acute pulmonary thromboembolism. Clin Chim Acta 409:112–116

    Article  CAS  PubMed  Google Scholar 

  12. Plenchette S, Filomenko R, Logette E (2004) Analyzing markers of apoptosis in vitro. Methods Mol Biol 281:313–331

    CAS  PubMed  Google Scholar 

  13. Lui YY, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YM (2002) Predominant hematopoietic origin of cf-DNA in plasma and serum after gender-mismatched bone marrow transplantation. Clin Chem 48:421–427

    CAS  PubMed  Google Scholar 

  14. Jahr S, Hentze H, Englisch S et al (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659–1665

    CAS  PubMed  Google Scholar 

  15. Sharov VG, Sabbah HN, Shimoyama H et al (1996) Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 148:141–149

    CAS  PubMed  Google Scholar 

  16. Park M, Shen YT, Gaussin V et al (2009) Apoptosis predominates in nonmyocytes in heart failure. Am J Physiol Heart Circ Physiol 297:H785–H791

    Article  CAS  PubMed  Google Scholar 

  17. Vescovo G, Volterrani M, Zennaro R et al (2000) Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart 84:431–437

    Article  CAS  PubMed  Google Scholar 

  18. Altenberger J, Parissis JT, Ulmer H, Poelzl G, LevoRep Investigators (2010) Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study). Eur J Heart Fail 12:186–192

    Article  CAS  PubMed  Google Scholar 

  19. Third Joint Task Force of European, other Societies on Cardiovascular Disease Prevention in Clinical Practice (2003) European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 10:1–78

    Article  Google Scholar 

  20. Sozzi G, Roz L, Conte D et al (2005) Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst 97:1848–1850

    Article  CAS  PubMed  Google Scholar 

  21. Sifakis S, Zaravinos A, Maiz N, Spandidos DA, Nicolaides KH (2009) First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol 201:472e1–472e7

    Article  Google Scholar 

  22. Chatterjee K, Massie B (2007) Systolic and diastolic heart failure: differences and similarities. J Card Fail 13:569–576

    Article  PubMed  Google Scholar 

  23. Karatzis EN, Giannakopoulou AT, Papadakis JE, Karazachos AV, Nearchou NS (2009) Myocardial performance index (Tei index): evaluating its application to myocardial infarction. Hellenic J Cardiol 50:60–65

    PubMed  Google Scholar 

  24. Lee Y, Gustafsson AB (2009) Role of apoptosis in cardiovascular disease. Apoptosis 14:536–548

    Article  PubMed  Google Scholar 

  25. Hatzistamou J, Kiaris H, Ergazaki M, Spandidos DA (1996) Loss of heterozygosity and microsatellite instability in human atherosclerotic plaques. Biochem Biophys Res Commun 225:186–190

    Article  CAS  PubMed  Google Scholar 

  26. Slawsky MT, Colucci WS, Gottlieb SS et al (2000) Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 102:2222–2227

    CAS  PubMed  Google Scholar 

  27. Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C (2008) Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol Ther 114:v184–v197

    Article  Google Scholar 

  28. Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT (2008) Novel biologic mechanisms of levosimendan and its effect on the failing heart. Exp Opin Investig Drugs 17:1143–1150

    Article  CAS  Google Scholar 

  29. Adamopoulos S, Parissis JT, Iliodromitis EK et al (2006) Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 98:102–106

    Article  CAS  PubMed  Google Scholar 

  30. Parissis JT, Adamopoulos S, Antoniades C et al (2004) Effects of levosimendan on circulating proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93:1309–1312

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Demetrios A. Spandidos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zaravinos, A., Tzoras, S., Apostolakis, S. et al. Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy. J Thromb Thrombolysis 31, 180–187 (2011). https://doi.org/10.1007/s11239-010-0527-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-010-0527-8

Keywords

Navigation